u 73122 Search Results


93
Thermo Fisher u73122
EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with <t>U73122</t> (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)
U73122, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pmc12044835-36-3-5?v=Thermo+Fisher
Average 93 stars, based on 1 article reviews
u73122 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology 108 inhibitors u73122
EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with <t>U73122</t> (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)
108 Inhibitors U73122, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/10__1128_slash_iai__00915___16-41-1-17?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
108 inhibitors u73122 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

96
Tocris bapta am
EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with <t>U73122</t> (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)
Bapta Am, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/10__1074_slash_jbc__m112__400234-48-4-8?v=Tocris
Average 96 stars, based on 1 article reviews
bapta am - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Tocris phospholipase d inhibitor u73122
EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with <t>U73122</t> (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)
Phospholipase D Inhibitor U73122, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/10__1074_slash_jbc__m117__782326-262-30-34?v=Tocris
Average 96 stars, based on 1 article reviews
phospholipase d inhibitor u73122 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

90
Funakoshi ltd 1-[6-[amino]hexyl]-1h-pyrrole-2,5-dione (u-73122)
EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with <t>U73122</t> (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)
1 [6 [Amino]Hexyl] 1h Pyrrole 2,5 Dione (U 73122), supplied by Funakoshi ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pm11834445-53-0-5?v=Funakoshi+ltd
Average 90 stars, based on 1 article reviews
1-[6-[amino]hexyl]-1h-pyrrole-2,5-dione (u-73122) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
ICN Pharmaceuticals u-73122
EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with <t>U73122</t> (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)
U 73122, supplied by ICN Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pm09294612-120-13-17?v=ICN+Pharmaceuticals
Average 90 stars, based on 1 article reviews
u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
FUJIFILM u-73122
A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor <t>U-73122</t> (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.
U 73122, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pmc01464193-90-0-4?v=FUJIFILM
Average 90 stars, based on 1 article reviews
u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
MedKoo Inc phosphatidylinositol-specific phospholipase c (pi-plc) inhibitor u-73122
A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor <t>U-73122</t> (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.
Phosphatidylinositol Specific Phospholipase C (Pi Plc) Inhibitor U 73122, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pmc06298919-49-0-9?v=MedKoo+Inc
Average 90 stars, based on 1 article reviews
phosphatidylinositol-specific phospholipase c (pi-plc) inhibitor u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
VASCO DRUG LABORATORIES u-73122
A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor <t>U-73122</t> (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.
U 73122, supplied by VASCO DRUG LABORATORIES, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pmc03660692-307-7-20?v=VASCO+DRUG+LABORATORIES
Average 90 stars, based on 1 article reviews
u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Chemie GmbH u-73122
A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor <t>U-73122</t> (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.
U 73122, supplied by Chemie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pm14500581-49-10-28?v=Chemie+GmbH
Average 90 stars, based on 1 article reviews
u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Federation of European Neuroscience Societies u-73122
A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor <t>U-73122</t> (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.
U 73122, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/pm12169114-83-61-51?v=Federation+of+European+Neuroscience+Societies
Average 90 stars, based on 1 article reviews
u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Pharmacia Upjohn LLC u-73122
A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor <t>U-73122</t> (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.
U 73122, supplied by Pharmacia Upjohn LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/u+73122/10__1152_slash_ajpheart__1994__266__6__h2388-213-55-66?v=Pharmacia+Upjohn+LLC
Average 90 stars, based on 1 article reviews
u-73122 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with U73122 (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)

Journal: Cell Communication and Signaling : CCS

Article Title: Head and neck squamous cell carcinoma-derived extracellular vesicles mediate Ca²⁺-dependent platelet activation and aggregation through tissue factor

doi: 10.1186/s12964-025-02215-x

Figure Lengend Snippet: EV-induced PLT aggregation and activation involve the coagulation cascade. PLTs were suspended in Tyrode’s buffer containing 2 mM Ca 2+ , and aggregation was monitored for 1000 s. (A) Schematic overview of used PLT aggregation inhibitors and their targets within the PLT activation and aggregation pathways. This graph was created using BioRender.com. (B) Role of phospholipase C (PLC) in EV-induced PLT aggregation. PLTs were pre-incubated with U73122 (10 µM; +; PLC inhibitor), without U73122 (-) or Dimethyl sulfoxide (DMSO; 1:250 dilution; ctrl) for 300 s, followed by the addition of SAS- or UD5 derived EVs (60 µg/mL). PLT aggregation was quantified as the area under the curve (AUC, n = 4–8). (C) Effect of FcγRIIa inhibition on PLT aggregation. PLTs were pre-incubated with (+) or without (-) the FcγRIIa-blocking antibody IV.3 (300 ng/mL) for 300 s in an aggregometer. IgG-coated E. coli (5 × 10⁷ bacteria/sample) or SAS and UD5 EVs (60 µg/mL) were then added to assess FcγRIIa-dependent PLT activation ( n = 3–9). (D) Involvement of PAR1 and PAR4 thrombin receptors in EV-induced PLT aggregation. PLTs were pre-treated with Vorapaxar (+; Vora.; 10 µM; PAR1 inhibitor) and BMS986120 (+; BMS; 10 µM; PAR4 inhibitor) or vehicle control (-; DMSO, 1:250 dilution) for 300 s, followed by the addition of SAS or UD5-derived EVs (60 µg/mL). Thrombin receptor activation was induced using TRAP (25 µM; thrombin receptor agonist) as a positive control ( n = 5–11). (E) PLTs were treated with the inhibitor PPACK (+, 1 µM) or DMSO control (-, 1:20,000 dilution) to block thrombin activity, and aggregation was assessed following stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM; positive control) ( n = 5–10). (F) PLT aggregation following treatment with the thrombin inhibitor hirudin (+, 2.5 µM) or H 2 O control (-, 1:200 dilution) was measured after stimulation with SAS and UD5 EVs (60 µg/mL) or TRAP (25 µM) ( n = 3–8). (G) Thrombin activity during PLT aggregation. Thrombin activity (IU/mL) was measured at 10 s, the start of aggregation, and at 50% aggregation. PLTs were incubated with SAS- or UD5-derived EVs (60 µg/mL), and supernatants were collected for analysis. PBS-treated PLTs served as controls ( n = 5, left graph; n = 4, right graph). Data are presented as the mean + SD from n ≥ 3 independent experiments. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test followed by Dunn’s post-hoc test for (B-D). One-way ANOVA followed by Bonferroni’s post-hoc test for (E, F). Two-way ANOVA followed by Tukey’s post-hoc test for (G)

Article Snippet: Inhibitors used included U73122 (#J62898.MCR, ThermoFisher Scientific), Phe-Pro-Arg-Chloromethylketone (PPACK, #sc-201291, Santa Cruz Biotechnology), Hirudin (#H0393-100UN, Merck), Vorapaxar (#23119, Cayman Chemical), and BMS986120 (#23497-01, Cayman Chemical).

Techniques: Activation Assay, Coagulation, Incubation, Derivative Assay, Inhibition, Blocking Assay, Bacteria, Control, Positive Control, Activity Assay

A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor U-73122 (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.

Journal:

Article Title: Involvement of Src tyrosine kinase and mitogen-activated protein kinase in the facilitation of calcium channels in rat nucleus of the tractus solitarius by angiotensin II

doi: 10.1113/jphysiol.2005.095307

Figure Lengend Snippet: A, typical superimposed ICa traces at the times indicated in the time course of graph B. B, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PLC inhibitor U-73122 (10 μm for 15 min before patch clamp experiments). C, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after 5, 10, 20 and 50 μm U-73122. Numbers in parentheses indicate the number of neurons tested. D, typical superimposed ICa traces at the times indicated in the time course graph E. E, typical time course of Ang II-induced facilitation of ICa in a neuron treated with PI3K inhibitor LY294002 (10 μm for 10 min before patch clamp experiments). Ang II (1 μm) was bath-applied during the time indicated by the filled bar.

Article Snippet: U-73122 was purchased from Wako Pure Chemical Industries (Osaka, Japan).

Techniques: Patch Clamp

A, comparison of ICa values in various conditions in the presence of DMSO in the pipette solution. Histogram demonstrating the degree of ICa values before application of any drugs, application of 1 μm Ang II, genistein alone in the pipette solution, genistein in the pipette solution + 1 μm Ang II, lavendustin A alone in the pipette solution, lavendustin A in the pipette solution + 1 μm Ang II, PD98,059 alone in the pipette solution and PD98,059 in the pipette solution + 1 μm Ang II. B, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after U-73122, LY294002, genistein, lavendustin A, PP2, PD98,059, U0126, SB202190 and SP600125. Numbers in parentheses indicate the number of neurons tested. *P < 0.05 compared with control, ANOVA.

Journal:

Article Title: Involvement of Src tyrosine kinase and mitogen-activated protein kinase in the facilitation of calcium channels in rat nucleus of the tractus solitarius by angiotensin II

doi: 10.1113/jphysiol.2005.095307

Figure Lengend Snippet: A, comparison of ICa values in various conditions in the presence of DMSO in the pipette solution. Histogram demonstrating the degree of ICa values before application of any drugs, application of 1 μm Ang II, genistein alone in the pipette solution, genistein in the pipette solution + 1 μm Ang II, lavendustin A alone in the pipette solution, lavendustin A in the pipette solution + 1 μm Ang II, PD98,059 alone in the pipette solution and PD98,059 in the pipette solution + 1 μm Ang II. B, histogram demonstrating the degree of ICa facilitation by 1 μm Ang II in control (untreated neurons), after U-73122, LY294002, genistein, lavendustin A, PP2, PD98,059, U0126, SB202190 and SP600125. Numbers in parentheses indicate the number of neurons tested. *P < 0.05 compared with control, ANOVA.

Article Snippet: U-73122 was purchased from Wako Pure Chemical Industries (Osaka, Japan).

Techniques: Transferring